Drugs / E6742
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04683185 | Dec 2020 → Jun 2021 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03082235 | Mar → Oct 2017 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05278663 | Apr 2022 → Sep 2023 | systemic lupus erythematosus | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07515014 | Mar 2026 → Aug 2028 expected | systemic lupus erythematosus | Eisai Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E6742 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07515014 ↗ |
| Action | Inhibit | “a dual antagonist of Toll-like receptors 7 and 8” PMID 39289029 ↗ Sep 2024 |
| Route | Oral | “Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.” NCT03082235 ↗ |